PEPTIDE GUIDE

What Is ACE-031?

ACE-031 is an experimental fusion protein designed to trap myostatin, activins and related signalling proteins before they bind to cell receptors. It combines the external ligand-binding part of activin receptor type IIB, shortened to ActRIIB, with the Fc portion of a human immunoglobulin G1 antibody.

It is often grouped with “peptides”, but that shorthand hides its identity. ACE-031 is a large, dimeric, glycosylated biologic rather than a short chain made by ordinary peptide synthesis. It was developed by Acceleron Pharma for muscle-wasting disorders.

ACE-031 reached a randomised trial in boys with Duchenne muscular dystrophy. The study reported signals in lean mass and bone measures, but it was stopped early after nosebleeds and small dilated skin blood vessels appeared. Functional improvement was not statistically established, and development did not produce an approved medicine.

Research statusDiscontinued experimental ActRIIB-Fc ligand trap
Compound typeActivin receptor type IIB-Fc fusion protein
Human evidenceSmall randomised DMD trial stopped early
ApprovalNot an approved medicine
Last reviewedSeptember 2026
THE SHORT ANSWER

ACE-031 is a soluble ActRIIB-Fc ligand trap. It binds several TGF-beta-superfamily ligands, not myostatin alone. In a small placebo-controlled Duchenne muscular dystrophy trial, investigators saw trends towards increased lean mass and bone mineral density and maintenance of six-minute walk distance, but the functional difference was not statistically significant. The study stopped after potential safety concerns involving epistaxis and telangiectasias. Those vascular findings are biologically important because related ligands help regulate blood vessels. ACE-031 is not an approved treatment, performance drug or equivalent of follistatin.

How does ACE-031 work?

Cell-surface ActRIIB normally receives signals from ligands including myostatin and activin A. Binding brings receptor components together and activates SMAD proteins inside the cell. In muscle, this signalling generally restrains growth.

ACE-031 circulates as a decoy. Its ActRIIB portion binds ligands, while its Fc portion supports dimer formation and extends persistence. By intercepting ligands, it reduces signalling through native receptors.

The word “myostatin inhibitor” is incomplete. ACE-031 binds more than myostatin. This broader ligand capture may produce a stronger muscle effect, but it can also disturb vascular, reproductive and metabolic pathways. Safety findings cannot be understood if the product is imagined as a perfectly selective switch.

Which signals can an ActRIIB ligand trap intercept?

Myostatin and activin A belong to the transforming growth factor beta superfamily. These ligands can bind type II receptors, which then recruit type I receptors and activate SMAD2 and SMAD3 inside the cell. In skeletal muscle, reducing this signalling can shift the balance towards greater fibre growth.

ACE-031 presents a soluble version of the ActRIIB binding surface. It can therefore capture any compatible circulating ligand, rather than recognizing one unique molecular target in the way a highly selective antibody might. Binding breadth was part of the reason the approach produced strong preclinical effects.

Breadth also creates the central safety problem. Activins and related ligands contribute to blood-vessel stability, reproductive signalling, bone turnover and blood-cell production. A change outside muscle is not necessarily an unrelated side effect; it may be evidence that the intended molecular trap is operating in several tissues at once.

What is an ActRIIB-Fc fusion protein?

The extracellular domain is the part of a receptor normally exposed outside a cell. Researchers can manufacture that domain as a soluble protein, so it floats rather than remaining attached to a cell membrane.

Fc is the tail region of an antibody. Fusing a receptor domain to Fc can make a two-armed molecule and prolong circulation through the body's antibody-recycling pathway. The result resembles an antibody biologic in size and manufacturing complexity.

This explains why ACE-031 is not “the same peptide” as ACE-083, follistatin or a myostatin antibody. Each intervention captures different ligands, reaches tissues differently and has its own clinical evidence.

How was ACE-031 developed?

Animal research with soluble ActRIIB constructs showed pronounced increases in muscle mass and strength, including in muscular-dystrophy models. Acceleron then conducted early human research in healthy postmenopausal women before studying boys with Duchenne muscular dystrophy.

Duchenne is caused by pathogenic variants in the DMD gene and absence of functional dystrophin. Muscle fibres are damaged repeatedly and progressively replaced by fat and fibrotic tissue. Increasing muscle size without correcting dystrophin does not necessarily stop that underlying process.

Why did Duchenne seem like a logical test disease?

Duchenne muscular dystrophy causes progressive weakness because dystrophin-deficient muscle fibres are mechanically fragile. A therapy that increased the amount or force of remaining muscle might, in principle, preserve function even without replacing dystrophin. This made myostatin-pathway inhibition a potential add-on strategy rather than a genetic cure.

The hypothesis contained an important uncertainty. Newly enlarged fibres would still lack functional dystrophin and remain exposed to contraction-related damage. Greater mass might improve reserve, but it could also fail to translate into endurance or durable mobility. Only functional and long-term outcomes could distinguish those possibilities.

What did the first human study show?

Before the Duchenne programme, ACE-031 was evaluated in a randomized, placebo-controlled, single-exposure study in healthy postmenopausal women. This population allowed investigators to examine pharmacokinetics, tolerability and body-composition signals without the rapid developmental changes of childhood.

The study reported dose-related pharmacodynamic effects, including an increase in lean body mass at higher exposure. Reported adverse effects included injection-site reactions and other generally mild events. A single-dose study can show that a pathway is engaged, but it cannot establish the safety of repeated suppression or clinical benefit in a muscle disease.

That distinction matters because the later Duchenne trial involved repeated administration to children with a progressive disorder. Evidence of lean-mass change in adults supported further research; it did not establish a treatment.

PeriodDevelopment
Preclinical periodActRIIB ligand traps increased muscle in animal models
Early human developmentSingle and escalating exposure studied pharmacology and body composition
2010 to 2011Placebo-controlled study conducted in ambulatory boys with Duchenne muscular dystrophy
Trial outcomeProgramme stopped early after vascular safety findings
Current positionNo approved ACE-031 medicine

What did the Duchenne trial involve?

The study was randomised, double-blind, placebo-controlled and dose escalating. Ambulatory boys received subcutaneous ACE-031 or placebo every two to four weeks. Safety was the main objective. Pharmacokinetics, body composition, bone measures and physical function were exploratory or secondary.

The study stopped after its second dosing regimen because of potential safety concerns involving epistaxis, meaning nosebleeds, and telangiectasias, which are visibly widened small blood vessels near the skin surface.

Researchers reported trends towards increased lean body mass and bone mineral density, reduced fat mass and maintenance of six-minute walk distance compared with decline in placebo. The walk difference was not statistically significant.

A trend is not proof. Early stopping reduced sample size and exposure, making efficacy and longer-term safety harder to estimate. Body-composition change is a pharmacodynamic signal, not necessarily improved daily function.

What did the trial actually measure?

The primary objective was safety. Pharmacokinetics described how ACE-031 concentrations changed over time, while pharmacodynamic measures asked whether the body responded to pathway inhibition. These included lean mass, fat mass, bone mineral density and functional assessments such as the six-minute walk test.

This hierarchy matters. A safety-focused, ascending-exposure study is not designed like a confirmatory efficacy trial. Several secondary outcomes moving in a favourable direction can generate a hypothesis, but early stopping, small groups and multiple comparisons make chance and imbalance harder to exclude.

The published report described no serious or severe adverse event attributed to ACE-031. Nevertheless, epistaxis and telangiectasias became more concerning as repeated exposure accumulated. Development decisions consider mechanism, recurrence and the population being treated, not only whether an event meets a regulatory definition of “serious”.

Why did nosebleeds and telangiectasias matter?

These findings suggested that ACE-031 affected more than muscle. Activin-family and bone-morphogenetic-protein signals participate in blood-vessel maintenance. Broad ligand trapping may therefore alter vascular surfaces.

Telangiectasias can be cosmetic in some settings, but in a new biologic they act as a visible marker of pathway activity. Nosebleeds show that the effect may have clinical consequences. The pattern resembled vascular effects later seen with some related ligand traps.

The trial report did not describe serious or severe adverse events caused by ACE-031, but “not serious” does not mean unimportant. A recurring, mechanism-related event in children can justify stopping development before more severe harm appears.

The findings also weakened the idea that ACE-031 behaved as a muscle-selective therapy. Visible small-vessel changes offered an external sign that related ligands were being trapped in vascular tissue. Nosebleeds added a clinical manifestation rather than an imaging or laboratory observation alone.

Stopping early was therefore informative, even though it left unanswered questions. It reduced the opportunity to learn whether vascular findings would resolve, plateau or progress with longer exposure. It also limited the ability to estimate frequency precisely or determine whether a narrower therapeutic window existed.

Did ACE-031 improve strength or walking?

The trial did not establish a statistically significant functional benefit. The reported maintenance trend in six-minute walk distance was encouraging but inconclusive.

Lean mass is not the same as contractile quality. In Duchenne, muscle structure, fibrosis, motor control, fatigue and cardiopulmonary function all influence walking. A larger imaging compartment may not translate into proportionate strength or preserved independence.

A definitive trial would need adequate sample size, pre-specified functional outcomes, sufficient duration and a design capable of distinguishing treatment from natural variability.

Why are lean mass, strength and function not interchangeable?

Lean body mass is usually estimated by imaging and includes tissue that is not body fat or bone mineral. A change can demonstrate a biological effect, but it does not show how much force the new tissue produces.

Strength tests measure force in selected movements. They are closer to muscle performance, yet they still may not predict walking, climbing stairs, rising from the floor or preserving independence. Functional outcomes integrate strength with joint range, balance, motor learning, fatigue, cardiac status and breathing.

In Duchenne, fat replacement and fibrosis can complicate body-composition interpretation. A therapy could alter a scan without correcting dystrophin deficiency or preventing ongoing fibre damage. For this reason, a credible efficacy programme would need converging evidence across body composition, strength, timed function and patient-important outcomes.

How is ACE-031 manufactured?

ACE-031 would be made by recombinant biotechnology. Engineered mammalian cells express the fused receptor-Fc protein, which is harvested from culture fluid and purified using several chromatography and filtration steps.

Manufacturing controls must establish amino-acid sequence, disulphide bonds, glycosylation, Fc dimerisation, ligand-binding potency and aggregate levels. Host-cell proteins, residual DNA, viruses, endotoxins and particles must be controlled.

Biological activity is not proven by molecular mass alone. A suitable assay needs to show that the product binds relevant ligands or blocks receptor signalling at a defined potency.

An unregulated product labelled ACE-031 cannot be assumed to reproduce the trial biologic. Large fusion proteins are especially vulnerable to misfolding, aggregation and loss of potency. Aggregates can also increase immune risk.

What would be needed to establish product identity?

For a receptor-Fc fusion protein, a useful analytical package would need more than a purity percentage. It should establish intact molecular mass, peptide sequence, disulphide arrangement, Fc dimer formation, glycosylation, aggregate and fragment levels, concentration and ligand-binding potency. Host-cell proteins, residual DNA, endotoxin, particles and sterility would also matter for an injectable preparation.

Because biological activity depends on three-dimensional structure, a material can have approximately the expected mass and still be inactive or unpredictably immunogenic. A cell-based assay showing inhibition of the relevant signalling pathway would provide different information from chromatography alone.

Even verified identity would not make the product clinically validated. The published programme did not establish a safe repeated-use regimen, durable benefit or acceptable long-term risk.

How does ACE-031 differ from follistatin-344?

FeatureACE-031Follistatin-344 programme
MoleculeEngineered ActRIIB receptor-Fc fusion proteinFollistatin precursor gene/protein form
Main human interventionRepeated subcutaneous fusion proteinLocal intramuscular AAV gene transfer
Ligand profileTraps myostatin, activins and related ligandsFollistatin binds several activin-family ligands
Human evidenceRandomised DMD trial stopped earlyVery small uncontrolled muscular-disease studies
Key concernVascular events including epistaxis and telangiectasiasBroad ligand effects plus gene-transfer risks
ApprovalNot approvedNot approved

They share a pathway theme, not product equivalence.

What are the broader safety uncertainties?

Potential concerns include bleeding or vascular changes, reproductive-endocrine effects, altered bone signalling, immune reactions and effects on organs expressing activin-family pathways. Long-lived pathway suppression could matter even after dosing stops.

Antibodies against the drug might change exposure or cross-react with related proteins. The small and shortened clinical programme cannot quantify uncommon events or risks from chronic use.

Heart and respiratory muscle are central to Duchenne disease, but increasing muscle mass does not guarantee benefit to either. Long-term organ-specific study would be necessary.

Why did later programmes pursue narrower approaches?

The wider myostatin field moved towards antibodies directed at myostatin itself, modified ligands and locally acting traps. The scientific aim was to retain muscle effects while reducing interference with other activin-family signals.

These later products are not evidence that ACE-031 works or is safe. They are separate molecules with different affinity, distribution and trial results. Some also increased muscle volume without producing convincing functional improvement, reinforcing the lesson that pathway engagement is not the same as patient benefit.

ACE-083, for example, was designed for local activity in an injected muscle rather than systemic exposure. It remains distinct from ACE-031 and cannot be used to infer an ACE-031 dose, safety profile or clinical outcome.

Is ACE-031 approved or prohibited in sport?

ACE-031 is not an FDA-, EMA- or UK-approved medicine. It should not be described as an available Duchenne treatment.

WADA prohibits myostatin-function modifiers, including agents that reduce or eliminate myostatin function. Athletes should treat ACE-031 as prohibited at all times.

What claims are not supported?

ACE-031 has not been established for bodybuilding, healthy ageing, recovery, fat loss or sports performance. It has not been shown to safely produce durable functional improvement in healthy people or patients.

The early DMD lean-mass signal does not supply a safe dose or cycle. Combining it with follistatin, growth hormone or other myostatin agents has no established safety basis and could broaden pathway suppression.

How strong is the evidence overall?

QuestionBest available evidenceWhat can reasonably be concluded
Does ACE-031 engage the pathway in humans?Early controlled studies with body-composition changesYes, pharmacodynamic activity was observed
Does it improve Duchenne function?Small trial stopped early; walking trend not statistically significantEfficacy was not established
Is repeated exposure acceptably safe?Vascular adverse effects halted developmentNo acceptable benefit-risk profile was demonstrated
Does it work in healthy adults or athletes?No adequate performance trialsClaims are unsupported
Can retail ACE-031 be equated with trial material?No validated equivalence evidenceNo

The evidence ceiling is real. ACE-031 has enough research to explain its mechanism, development logic and failure point in detail, but not enough to support administration guidance or claims of useful performance enhancement.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is ACE-031 a peptide?

It is a large recombinant fusion protein, not a conventional short peptide.

Is it a myostatin inhibitor?

Yes, but it traps several related ligands and is not myostatin-specific.

What does ActRIIB-Fc mean?

It combines the external ligand-binding part of activin receptor type IIB with an antibody Fc region.

Was ACE-031 tested in humans?

Yes, including a small randomised trial in boys with Duchenne muscular dystrophy.

Why was the trial stopped?

Potential safety concerns arose from nosebleeds and telangiectasias.

Did it increase lean mass?

The trial showed trends in lean mass and other body-composition measures.

Did it improve walking?

There was a non-significant trend, not established functional efficacy.

Is ACE-031 approved?

No.

Is ACE-031 the same as ACE-083?

No. ACE-083 was a related locally acting ligand trap with different design and development.

Is it the same as follistatin?

No. Both affect activin-family signalling but are different proteins.

Can online ACE-031 be assumed genuine?

No. Identity, folding, glycosylation, potency, aggregates and sterility require validated testing.

Does it build muscle in healthy adults?

No controlled evidence establishes safe, functional muscle gain in that population.

Is it banned in sport?

Yes, it falls within prohibited myostatin-function modification.

Are trial levels personal-use guidance?

No. This guide does not provide administration instructions.

RESEARCH AND MEDICAL NOTICE

This page explains published ACE-031 research. It does not recommend use, provide doses or cycles, or advise combining it with any compound.

Research reviewed through September 2026.